Your SlideShare is downloading. ×
0
GestationalDiabetes Presented by: Dr. Neville M.G & Dr. Jonas L.F ( O&G Housemen SGH)    Supervisor: Dr Muniswaran Ganesha...
   Gestational diabetes is carbohydrate intolerance of    variable severity, with onset or first recognition of    hyperg...
Introduction• Represents most common metabolic complication during  pregnancy; early manifestation of type 2 diabetes• Stu...
PATHOPHYSIOLOGY   Early in pregnancy, maternal estrogen and progesterone increase and promote    pancreatic ß-cell hyperp...
   GDM results when there is delayed or insufficient insulin secretion in the    presence of increasing peripheral resist...
Risk factors (WHO/NICE)Patients were considered to be risk-factor positive if any of the  following is present: age 35 ye...
   In the public health service in Malaysia, screening for    gestational diabetes is done selectively where only    pati...
Effects on Pregnant Women   Pre-eclampsia   Polyhydramnios   Operative delivery in pregnancies complicated with    GDM/...
Effects on Fetus•   increased rate of stillbirths in untreated GDM•   increased risk of macrosomia    (fetal weight >90th ...
 Respiratory distress symptom Neonatal jaundice/hyperbilirubinemiaLong Term Outcome: IGT in adolescent children By 8 y...
How to Diagnose GDM FBS?? RBS?? Glucosuria?? MOGTT??
 ANSWER:MOGTTSo how’s it done??Screening for GDM is performed with a 75-g oral  glucose load given between 24 and 28 week...
WHO              HAPO   ADA            IADPSGFasting   7.0              5.1    5.3            5.12 hours   7.8            ...
HAPO STUDY:   This was an international multicentre observation    study in which over 23,000 pregnant women    were asse...
ACHOIS Women with gestational diabetes (WHO criteria)  were randomized either to an intervention group  which received di...
MANAGEMENT: Exercise . Jovanovic-Peterson and associates studied 19 women  with GDM, assigning 9 to dietary treatment and...
Diet control   ADA has recommended dietary therapy to    start with 2,000–2,500 kcal/day (35 kcal/kg    present pregnancy...
Insulin The ACOG criteria for initiating insulin therapy  include a fasting plasma glucose level 5.8 mmol/l and  2-hour p...
OHA 1) Gilbenclamide (sulphonylurea): MOA: enhance insulin secretion  by beta cells. Older sulphonylurea medications such...
Timing and mode of deliveryTiming:-Uncomplicated, well controlled DM not requiring insulin with  normal fetal growth- 38 t...
 Look for unrecognized DM2 or GDM at 1st prenatal    visit if risk factors   New criteria for diagnosing GDM ’ 2-hr, 75 ...
The end
Upcoming SlideShare
Loading in...5
×

Gdm ho presentation

7,430

Published on

Published in: Health & Medicine
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
7,430
On Slideshare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
174
Comments
0
Likes
3
Embeds 0
No embeds

No notes for slide

Transcript of "Gdm ho presentation"

  1. 1. GestationalDiabetes Presented by: Dr. Neville M.G & Dr. Jonas L.F ( O&G Housemen SGH) Supervisor: Dr Muniswaran Ganeshan (MRCOG, M MED O&G)
  2. 2.  Gestational diabetes is carbohydrate intolerance of variable severity, with onset or first recognition of hyperglycaemia during pregnancy. Gestational diabetes is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during third trimester).
  3. 3. Introduction• Represents most common metabolic complication during pregnancy; early manifestation of type 2 diabetes• Studies have shown that gestational hyperglycaemia is associated with highe incidence of adverse maternal and fetal outcomes than is seen in normal pregnancy• High proportion (>50%) have GDM in the subsequent pregnancy• Increased risk of subsequent T2DM - approx. 50 % of women with GDM progressed to DM within 5 years duration - 35 to 60% of women develop T2DM within 10 years after being diagnosed w GDM.
  4. 4. PATHOPHYSIOLOGY Early in pregnancy, maternal estrogen and progesterone increase and promote pancreatic ß-cell hyperplasia and increased insulin release As pregnancy progresses, increased levels of human placental lactogen, cortisol, prolactin, progesterone, and estrogen lead to insulin resistance in peripheral tissues. Table 1 describes the diabetogenic potency and time of peak effect of these hormones. The timing of these hormonal events is important in regard to scheduling testing for GDM Hormone Peak elevation (weeks) Diabetogenic potency Prolactin 10 Weak Estradiol 26 Very weak HPL 26 Moderate Cortisol 26 Very strong Progesterone 32 Strong Adapted from Jovanovic-Peterson L, Peterson C: Review of gestational diabetes mellitus and low-calorie diet and physical exercise as therapy. Diabetes Metab Rev 12:287-308, 1996.
  5. 5.  GDM results when there is delayed or insufficient insulin secretion in the presence of increasing peripheral resistance
  6. 6. Risk factors (WHO/NICE)Patients were considered to be risk-factor positive if any of the following is present: age 35 years and above previous macrosomic baby with birth weight 4.0kg or more previous unexplained still birth previous baby with congenital abnormally previous pregnancy with gestational diabetes mellitus history of Diabetes Mellitus in first degree relatives Obese or pre-pregnancy weight more than 80kg, BMI > 30 Ethnicity
  7. 7.  In the public health service in Malaysia, screening for gestational diabetes is done selectively where only patients with risk factors are screened and diagnosed using a 1-step 75g OGTT. This is done at least once at or around 24-28 weeks gestation, unless there are indications for it to be done earlier. However, as Asian ethnicity is considered a risk factor, selectively screening our women without regard to their Asian background may results in gross under-detection of gestational diabetes (~50%) On the other hand, to have all pregnant women undergo the 75g OGTT may be cumbersome and have some economic implications, particularly in low resource areas.
  8. 8. Effects on Pregnant Women Pre-eclampsia Polyhydramnios Operative delivery in pregnancies complicated with GDM/length of hospital stay, risks of infection. significant risk of developing diabetes later in life higher triglycerides,free fatty acids,and lower high-density level (HDL) cholesterol. (cardiovascular risk)
  9. 9. Effects on Fetus• increased rate of stillbirths in untreated GDM• increased risk of macrosomia (fetal weight >90th percentile for gestational age or >4 kg)• fetal hyperinsulinemia and subsequently increase fetal growth• shoulder dystocia is increased 2-6X; brachial plexus injury• Neonatal hypoglycemia. In severe case, intravenous (IV) glucose solution may needed or else the baby will suffer brain damage
  10. 10.  Respiratory distress symptom Neonatal jaundice/hyperbilirubinemiaLong Term Outcome: IGT in adolescent children By 8 years of age, 50% of children of diabetic mothers had weights above the 90th percentile compared to children of women without diabetes high incidence of obesity neurodevelopmental course- child’s poorer performance on standard measures of psychomotor development at 6 and 9 years of age.
  11. 11. How to Diagnose GDM FBS?? RBS?? Glucosuria?? MOGTT??
  12. 12.  ANSWER:MOGTTSo how’s it done??Screening for GDM is performed with a 75-g oral glucose load given between 24 and 28 weeks gestation, with venous plasma glucose level taken pre and 2 hours post. The screening test is performed at a time when the diabetogenic effects of pregnancy are peaking.
  13. 13. WHO HAPO ADA IADPSGFasting 7.0 5.1 5.3 5.12 hours 7.8 8.5 8.6 8.5notes One abnormal Two abnormal One abnormal value required value required value required
  14. 14. HAPO STUDY: This was an international multicentre observation study in which over 23,000 pregnant women were assessed for glucose intolerance using the 75 g OGTT. The results remained blinded, providing fasting glucose <5.8 mmol/l and 2-h glucose <11.1 mmol/l. The study showed relation between high blood glucose levels with macrosomia n neonatal hypoglycemia Other outcomes: caesarean section, shoulder dystocia, birth injury, pre-eclampsia, premature delivery, admission to neonatal intensive care and neonatal hyperbilirubinaemia
  15. 15. ACHOIS Women with gestational diabetes (WHO criteria) were randomized either to an intervention group which received dietary advice, glucose monitoring and insulin therapy if required, or a control group receiving usual care. The intervention group showed a significantly lower rate (1% vs 4%) of serious perinatal complications including death, shoulder dystocia, bone fracture and nerve palsy. rates of caesarean section were similar between the intervention and the control group however there was an increased incidence of induction of labour in the intervention group (39% vs 29%).
  16. 16. MANAGEMENT: Exercise . Jovanovic-Peterson and associates studied 19 women with GDM, assigning 9 to dietary treatment and 10 to diet plus 20 minutes of monitored exercise 3 times a week for 6 weeks. They found a significantly lower OGTT and fasting blood glucose in patients assigned to the exercise group beginning 6 weeks after initiating therapy. What type of exercise??Non weight bearing (ex: swimming, cycling, brisk walking)
  17. 17. Diet control ADA has recommended dietary therapy to start with 2,000–2,500 kcal/day (35 kcal/kg present pregnancy weight), with 50–60% carbohydrates (complex, high fiber), 10– 20% protein, and 25–30% fat (<10% saturated). New ADA recommendations specify a protein level of 10–20% of calories but now allow greater flexibility in the levels of carbohydrate and fat.
  18. 18. Insulin The ACOG criteria for initiating insulin therapy include a fasting plasma glucose level 5.8 mmol/l and 2-hour plasma postprandial levels 6.6 mmol/l. Total insulin doses can be calculated and given with split dosing by three injections. If insulin is required, the target plasma glucose levels are: fasting 1hour 2 hours 2-6 am 3.3-5.8 mmol/l Not > 7.2-7.8 < 6.7 mmol/l 3.3- 5.0 mmol/l mmol/l
  19. 19. OHA 1) Gilbenclamide (sulphonylurea): MOA: enhance insulin secretion by beta cells. Older sulphonylurea medications such as tolbutamide and chlorpropamide can cause fetal hyperinsulinaemia. Glibenclamide has minimal passage across the placenta. Study: A trial published in 2000 randomized 404 women with gestational diabetes to receive either glibenclamide or insulin treatment. Results: no difference in the glycaemic control achieved between the two groups and no significant differences in rates of macrosomia or metabolic neonatal complication. 2) Metformin: MOA: increase insulin sensitivity. Study: MiG trial randomized 751 women to insulin or metformin treatment with insulin supplementation if required. Results:There was no difference in peri-natal morbidity between the two groups. 46% of the metformin group received supplemental insulin to meet glucose targets.
  20. 20. Timing and mode of deliveryTiming:-Uncomplicated, well controlled DM not requiring insulin with normal fetal growth- 38 to 40 weeks-GDM requiring insulin therapy- 38 weeks/earlier if indicatedMode Of Delivery: Studies have documented an increase in the rate of shoulder dystocia when macrosomia is suspected. Consequently, estimated fetal weight plays an important role in the decision- making process for route of delivery. When it is suspected that the fetus is macrosomic, cesarean delivery should be considered. Providers must remember that ultrasonography has a range of error of ±10–15% in estimating fetal weight at term.
  21. 21.  Look for unrecognized DM2 or GDM at 1st prenatal visit if risk factors New criteria for diagnosing GDM ’ 2-hr, 75 g OGTT Increased no. of women with GDM Rx hyperglycemia in pregnancy to prevent maternal & fetal complications Lifestyle modifications: diet & exercise (during & after pregnancy) Pharmacologic options: MFM, Glyburide, Insulin Screen for DM2 or pre-diabetes at 6-12 wks post- partum
  22. 22. The end
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×